Biotech Company Secures $453 Million Award For Covid-19 Oral Pill Candidate

Vaxart, Inc. (Nasdaq: VXRT), a biotechnology company known for its innovative oral vaccines, has announced a significant milestone in the development of its COVID-19 oral pill vaccine candidate. The company received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle (RRPV), a consortium funded by the Biomedical Advanced Research and Development Authority (BARDA). PART OF THE Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), this funding aims to support a Phase 2b comparative study evaluating Vaxart’s oral vaccine against an FDA-approved mRNA vaccine comparator. $Vaxart(VXRT.US)$